Tenet Healthcare Corporation (NYSE:THC) Receives Consensus Rating of “Moderate Buy” from Brokerages

Tenet Healthcare Corporation (NYSE:THC) has been given a consensus rating of “Moderate Buy” by the twenty-two ratings firms that are presently covering the stock, Marketbeat.com reports. Four equities research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $233.8125.

THC has been the subject of several analyst reports. Royal Bank Of Canada upped their price target on Tenet Healthcare from $230.00 to $252.00 and gave the stock an “outperform” rating in a research note on Thursday, October 30th. JPMorgan Chase & Co. raised their target price on shares of Tenet Healthcare from $200.00 to $230.00 and gave the stock an “overweight” rating in a research note on Thursday, November 13th. UBS Group boosted their price target on shares of Tenet Healthcare from $238.00 to $260.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Zacks Research lowered Tenet Healthcare from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Finally, Cowen reissued a “buy” rating on shares of Tenet Healthcare in a research note on Wednesday.

Insider Activity at Tenet Healthcare

In other news, Director Nadja West sold 2,178 shares of the company’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $197.47, for a total transaction of $430,089.66. Following the transaction, the director directly owned 28,480 shares of the company’s stock, valued at $5,623,945.60. This represents a 7.10% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Tammy Romo sold 645 shares of the firm’s stock in a transaction dated Wednesday, November 5th. The shares were sold at an average price of $205.20, for a total transaction of $132,354.00. Following the completion of the sale, the director owned 34,866 shares of the company’s stock, valued at $7,154,503.20. This trade represents a 1.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 45,500 shares of company stock valued at $9,247,071 over the last 90 days. Company insiders own 0.81% of the company’s stock.

Institutional Trading of Tenet Healthcare

Large investors have recently bought and sold shares of the company. Diversified Trust Co. boosted its stake in shares of Tenet Healthcare by 99.9% during the 4th quarter. Diversified Trust Co. now owns 4,287 shares of the company’s stock worth $852,000 after purchasing an additional 2,142 shares during the last quarter. Fulton Bank N.A. lifted its stake in shares of Tenet Healthcare by 69.6% during the fourth quarter. Fulton Bank N.A. now owns 1,805 shares of the company’s stock valued at $359,000 after buying an additional 741 shares during the period. Wealth Enhancement Advisory Services LLC grew its stake in Tenet Healthcare by 13.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 30,661 shares of the company’s stock worth $6,390,000 after acquiring an additional 3,629 shares during the period. NorthCrest Asset Manangement LLC raised its holdings in Tenet Healthcare by 23.1% in the 4th quarter. NorthCrest Asset Manangement LLC now owns 3,983 shares of the company’s stock valued at $825,000 after acquiring an additional 748 shares during the last quarter. Finally, Wedmont Private Capital boosted its holdings in shares of Tenet Healthcare by 2.5% during the fourth quarter. Wedmont Private Capital now owns 2,088 shares of the company’s stock worth $422,000 after purchasing an additional 50 shares during the last quarter. Institutional investors and hedge funds own 95.44% of the company’s stock.

Tenet Healthcare Price Performance

Shares of NYSE:THC opened at $201.46 on Friday. Tenet Healthcare has a one year low of $109.82 and a one year high of $222.82. The stock has a market capitalization of $17.71 billion, a price-to-earnings ratio of 13.81, a PEG ratio of 0.85 and a beta of 1.41. The company has a 50-day simple moving average of $202.22 and a 200-day simple moving average of $189.94. The company has a debt-to-equity ratio of 2.27, a quick ratio of 1.64 and a current ratio of 1.71.

Tenet Healthcare (NYSE:THC) last issued its quarterly earnings results on Tuesday, October 28th. The company reported $3.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.33 by $0.37. Tenet Healthcare had a return on equity of 25.11% and a net margin of 6.49%.The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.26 billion. During the same quarter in the previous year, the firm posted $2.93 EPS. The firm’s revenue for the quarter was up 3.2% on a year-over-year basis. Tenet Healthcare has set its FY 2025 guidance at 15.930-16.26 EPS. On average, analysts predict that Tenet Healthcare will post 12.24 EPS for the current year.

About Tenet Healthcare

Tenet Healthcare Corporation (NYSE: THC) is a diversified American healthcare services company that owns and operates acute care hospitals and a broad range of outpatient facilities. Its portfolio includes general acute-care hospitals, specialty hospitals, ambulatory surgery centers, urgent care and diagnostic imaging centers, and other ancillary service locations. Tenet’s operations are oriented around delivering inpatient and outpatient clinical care across multiple medical specialties, with an emphasis on surgical services, emergency care, and advanced diagnostics.

In addition to facility-based care, Tenet provides integrated services designed to support clinical operations and improve patient access and care coordination.